Fig. 4.

Effect of HQ in combination with 5-FU or capecitabine on tumor growth. HQ was orally administered twice a day, 5 times a week, and 5-FU was i.p. administered once a week for 6 weeks to MC38 tumor-bearing C57BL/6 mice. Tumor volume (A) and body weight (B) were determined twice a week. C, D HQ was administered daily, and capecitabine (CAP) was orally administered 7 days on/7 days off for 6 weeks to MC38-bearing C57BL/6 mice. Tumor volume (C) and body weight (D) were determined twice a week. Measurements represent the mean ± SD (7 mice per group). **, p < 0.01